BDP1 and ovarian serous adenocarcinoma: In line with consideration of BDP1 expression in the context of TP53 mutations, we also analyzed TP53 expression for relapse‐free survival at 12 months in response to both platin and taxane in serous ovarian cancer, Figure 5D, to determine its status as a predictive biomarker.